Comparative Pharmacology
Head-to-head clinical analysis: GEOPEN versus OMNIPEN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GEOPEN versus OMNIPEN N.
GEOPEN vs OMNIPEN-N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbenicillin is a bactericidal penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has activity against Gram-negative and some Gram-positive bacteria.
Omnipen-N (ampicillin sodium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with transpeptidation and resulting in cell lysis.
2 g intravenously every 6 hours for susceptible infections.
250-500 mg orally every 6 hours for adults; for severe infections, up to 1 g every 6 hours.
None Documented
None Documented
Terminal half-life 4-6 hours in normal renal function; prolonged to 10-20 hours in moderate renal impairment (CrCl 10-50 mL/min) and up to 30-50 hours in severe impairment (CrCl <10 mL/min).
30-60 minutes (normal renal function); prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min).
Renal: 80-90% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <2%.
Primarily renal (80-90% unchanged via tubular secretion); minor biliary/fecal (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic